Alixia alternatives
TL;DR: 12 companies doing similar work to Alixia in Healthcare, ranked by how closely they match what Alixia actually does — not just by category.
How this list was built: every company here is Y Combinator-backed and shares at least one category with Alixia. They are scored on how closely their own description overlaps with Alixia's, and all facts shown come from the YC company records — nothing is estimated.
What are the best alternatives to Alixia?
| Alternative | What it does | Batch | Team | Status |
|---|---|---|---|---|
| Mind Emulation Foundation | — | Winter 2018 | 1 | Active |
| ResistanceBio | We solve drug resistance for cancer | Winter 2019 | 15 | Inactive |
| Excepgen | — | Winter 2019 | 3 | Active |
| Nuntius Therapeutics | Cell-specific genetic medicines | Winter 2021 | 2 | Active |
| Atlas Discovery | AI-native pharma company | Summer 2026 | 3 | Active |
| Asher Bio | We build better immunotherapies | Summer 2019 | 3 | Active |
| Guardian Bio | Dendritic cell-based platform for cancer therapy | Summer 2022 | 2 | Active |
| GEn1E Lifesciences | AI platform accelerating therapies for rare & inflammatory diseases. | Summer 2019 | — | Active |
| Reverie Labs | Engineering next-generation, brain-penetrant cancer therapies. | Winter 2018 | 29 | Inactive |
| Gerostate Alpha | Developing novel therapeutics for aging and chronic disease | Summer 2018 | 6 | Inactive |
| Serinus Biosciences | Combinations therapy by rational design | Summer 2022 | 6 | Active |
| Velorum Therapeutics | Breakthrough medicines unlocking the biology of heme | Winter 2024 | 5 | Active |
Is Alixia still active?
Alixia is still operating, so switching is a choice rather than a forced migration. Compare on fit and price rather than urgency.
How was this list put together?
Every company here is Y Combinator-backed and shares at least one category with Alixia. They are then ranked on how closely their own description overlaps with Alixia's, so the closest matches come first rather than whoever happens to share a tag.